Marina oversees Novotech’s full ECD infrastructure, leading the strategy and execution of programs that advance therapeutic assets from preclinical research through first-in-human studies, with the ultimate goal of supporting clinical proof of concept. Previously, Marina led Novotech’s global therapeutic strategy team, providing strategic oversight across Oncology, Infectious Disease, CNS, immune-mediated diseases, and ATMPs. Earlier in her career, she led pharmacy functions within a Phase I unit, including building and commissioning a GMP clean room and establishing the supporting quality system; she is a registered Pharmacist in Australia.